BR112018071972A2 - métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos. - Google Patents
métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos.Info
- Publication number
- BR112018071972A2 BR112018071972A2 BR112018071972-2A BR112018071972A BR112018071972A2 BR 112018071972 A2 BR112018071972 A2 BR 112018071972A2 BR 112018071972 A BR112018071972 A BR 112018071972A BR 112018071972 A2 BR112018071972 A2 BR 112018071972A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- liver
- defensin
- methods
- catelicidine
- Prior art date
Links
- 210000003445 biliary tract Anatomy 0.000 title abstract 2
- 210000004185 liver Anatomy 0.000 title abstract 2
- 208000019423 liver disease Diseases 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 102000018568 alpha-Defensin Human genes 0.000 title 1
- 108050007802 alpha-defensin Proteins 0.000 title 1
- 102000012265 beta-defensin Human genes 0.000 title 1
- 108050002883 beta-defensin Proteins 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 201000007270 liver cancer Diseases 0.000 title 1
- 208000014018 liver neoplasm Diseases 0.000 title 1
- 210000000496 pancreas Anatomy 0.000 title 1
- 208000015163 Biliary Tract disease Diseases 0.000 abstract 1
- 102000000541 Defensins Human genes 0.000 abstract 1
- 108010002069 Defensins Proteins 0.000 abstract 1
- 208000016222 Pancreatic disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Marine Sciences & Fisheries (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
a presente invenção refere-se a métodos para tratamento ou prevenção de distúrbios de fígado, trato biliar, e pancreático por administração de uma ou mais defensinas. também está incluído dentro do escopo da descrição tratamento de determinados distúrbios metabólicos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201670276 | 2016-04-29 | ||
DKPA201670276 | 2016-04-29 | ||
DKPA201670484 | 2016-07-01 | ||
DKPA201670484 | 2016-07-01 | ||
PCT/DK2017/050132 WO2017186250A1 (en) | 2016-04-29 | 2017-04-28 | Treatment of liver, biliary tract and pancreatic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018071972A2 true BR112018071972A2 (pt) | 2019-02-26 |
Family
ID=58992579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018071972-2A BR112018071972A2 (pt) | 2016-04-29 | 2017-04-28 | métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20190192626A1 (pt) |
EP (1) | EP3448409A1 (pt) |
JP (1) | JP2019514908A (pt) |
KR (1) | KR102465341B1 (pt) |
CN (1) | CN109414474B (pt) |
AU (1) | AU2017258242B2 (pt) |
BR (1) | BR112018071972A2 (pt) |
CA (1) | CA3022497A1 (pt) |
RU (1) | RU2740913C2 (pt) |
SG (1) | SG11201809086YA (pt) |
WO (1) | WO2017186250A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102244161B1 (ko) * | 2018-08-31 | 2021-04-26 | 주식회사 나이벡 | 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도 |
AU2020207527A1 (en) | 2019-01-07 | 2021-08-19 | Aesculus Bio Aps | Defensin fragments for use in therapy or prophylaxis |
CN110279851A (zh) * | 2019-07-05 | 2019-09-27 | 浙江大学 | Defa4细胞因子在制备治疗肝功能衰竭药剂中的应用 |
CN114058694A (zh) * | 2021-11-29 | 2022-02-18 | 上海市普陀区中心医院 | Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用 |
KR20240068432A (ko) * | 2022-11-10 | 2024-05-17 | 을지대학교 산학협력단 | 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
DE4343591A1 (de) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
CA2655022A1 (en) * | 2006-06-20 | 2007-12-27 | Lipopeptide Ab | Use cathelicidin antimicrobial protein (hcap18 ) as anticancer agent |
WO2008115390A2 (en) * | 2007-03-16 | 2008-09-25 | The Hamner Institutes For Health Sciences | Methods of using defensins to treat diabetes |
US8906847B2 (en) | 2008-02-01 | 2014-12-09 | Ascendis Pharma A/S | Prodrug comprising a drug linker conjugate |
JP2011528333A (ja) | 2008-07-18 | 2011-11-17 | ノボザイムス アデニウム バイオテック アクティーゼルスカブ | 哺乳動物のベータ・ディフェンシンを用いた、炎症性腸疾患の治療 |
US9493545B2 (en) | 2009-02-11 | 2016-11-15 | Albumedix A/S | Albumin variants and conjugates |
CN103906528A (zh) * | 2011-06-24 | 2014-07-02 | 安米林药品有限责任公司 | 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法 |
WO2013006692A2 (en) * | 2011-07-06 | 2013-01-10 | The General Hospital Corporation | Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) |
WO2013007596A2 (en) * | 2011-07-08 | 2013-01-17 | Novozymes A/S | Oral treatment of inflammatory bowel disease |
SG11201500682WA (en) * | 2012-09-07 | 2015-02-27 | Sanofi Sa | Fusion proteins for treating a metabolic syndrome |
CN104971343B (zh) * | 2015-07-13 | 2018-02-02 | 韩源平 | 防御素在制备治疗代谢综合征药物方面的应用 |
CN105504063B (zh) * | 2015-10-19 | 2019-10-01 | 中国医学科学院医药生物技术研究所 | 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用 |
WO2017185549A1 (zh) * | 2016-07-30 | 2017-11-02 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法2 |
CN114075585A (zh) * | 2020-08-18 | 2022-02-22 | 弈柯莱生物科技(上海)股份有限公司 | 一种β-烟酰胺单核苷酸的制备方法 |
CN112795606B (zh) * | 2021-04-14 | 2021-07-27 | 深圳瑞德林生物技术有限公司 | 一种β-烟酰胺单核苷酸的酶催化合成方法 |
CN114107160A (zh) * | 2021-12-27 | 2022-03-01 | 浙江工业大学 | 一种烟酰胺核糖激酶基因工程菌及其应用 |
-
2017
- 2017-04-28 WO PCT/DK2017/050132 patent/WO2017186250A1/en active Search and Examination
- 2017-04-28 EP EP17727094.9A patent/EP3448409A1/en active Pending
- 2017-04-28 BR BR112018071972-2A patent/BR112018071972A2/pt not_active IP Right Cessation
- 2017-04-28 AU AU2017258242A patent/AU2017258242B2/en active Active
- 2017-04-28 SG SG11201809086YA patent/SG11201809086YA/en unknown
- 2017-04-28 CN CN201780039341.1A patent/CN109414474B/zh active Active
- 2017-04-28 RU RU2018141326A patent/RU2740913C2/ru active
- 2017-04-28 US US16/097,072 patent/US20190192626A1/en active Pending
- 2017-04-28 KR KR1020187033643A patent/KR102465341B1/ko active IP Right Grant
- 2017-04-28 JP JP2018556275A patent/JP2019514908A/ja not_active Ceased
- 2017-04-28 CA CA3022497A patent/CA3022497A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3448409A1 (en) | 2019-03-06 |
CN109414474B (zh) | 2024-07-02 |
KR20190003592A (ko) | 2019-01-09 |
RU2018141326A3 (pt) | 2020-08-06 |
WO2017186250A1 (en) | 2017-11-02 |
RU2740913C2 (ru) | 2021-01-21 |
JP2019514908A (ja) | 2019-06-06 |
CN109414474A (zh) | 2019-03-01 |
RU2018141326A (ru) | 2020-05-29 |
CA3022497A1 (en) | 2017-11-02 |
AU2017258242B2 (en) | 2024-04-04 |
SG11201809086YA (en) | 2018-11-29 |
AU2017258242A1 (en) | 2018-11-29 |
KR102465341B1 (ko) | 2022-11-09 |
US20190192626A1 (en) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018071972A2 (pt) | métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos. | |
CL2019000979A1 (es) | Composiciones y anticuerpos anti-lag-3. | |
BR112017011536A2 (pt) | terapias de combinação | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
BR112019002538A2 (pt) | uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral | |
EA201691872A1 (ru) | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств | |
BR112019010646A2 (pt) | métodos de tratamento de condições inflamatórias | |
EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
BR112015024530A2 (pt) | composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto | |
DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
BR112015027682A2 (pt) | Uso de sobetirome no tratamento de doenças ou condições associadas com a desmielinização ou mielinização insuficiente | |
BR112015021371A2 (pt) | uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
BR112014011896A2 (pt) | agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr) | |
CL2019002671A1 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1. | |
BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
BR112018000212A2 (pt) | uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer | |
IN2015DN00376A (pt) | ||
MX2019010994A (es) | Metodos para tratar enfermedades y trastornos mediados por el complemento. | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112019005351A2 (pt) | terapia combinada com agonistas de cnp de liberação controlada | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
AU2018264384A1 (en) | Solid forms of berberine ursodeoxycholate and compositions and methods thereof | |
BR112018069930A2 (pt) | agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2772 DE 20/02/2024. |